间歇性血液透析患者厄他培南的药代动力学与最佳剂量研究
这项前瞻性、单中心、开放标签研究纳入7例接受血液透析的非感染住院患者,单次静脉给予厄他培南1 g后评估药代动力学参数。结果显示厄他培南在血液透析患者中半衰期延长(平均19.3±6.6 h),作者据此提出血液透析后每周三次1 g的给药方案可能产生药效学上充分的暴露,但临床疗效与安全性尚需进一步研究。
要点
- 血液透析患者中厄他培南消除半衰期延长至19.3±6.6 h
- 单次静脉1 g后AUCinf为7494±1424 h·µg/mL,峰浓度为343±48 µg/mL
- 作者建议血液透析后每周三次1 g,但需进一步验证临床疗效与安全性
核心结论
- 厄他培南在血液透析患者中半衰期延长,考虑非肾清除及高效透析约70%的清除率,血液透析后每周三次1 g可能达到药效学上充分的暴露以发挥潜在抗菌疗效。
- 该剂量的临床疗效与安全性仍需在延长疗程的研究中进一步评估。
研究设计与样本
- 前瞻性、单中心、开放标签研究。
- 纳入7例接受血液透析的非感染住院患者。
- 单次静脉给予厄他培南1 g,给药前及给药后0.5、1、2、6、12、48小时采血。
- 厄他培南浓度采用经验证的液相色谱质谱法测定。
主要发现
- 静脉推注1 g后血浆浓度下降相对缓慢,平均±标准差消除半衰期为19.3±6.6 h。
- 给药后观察到的最大平均血浆浓度为343±48 µg/mL,各受试者血浆浓度相似。
- 全身血浆清除率平均±标准差为2±0.5 mL/min,稳态分布容积为3295±1187 mL。
- 0 h至无穷大的曲线下面积(AUCinf)为7494±1424 h·µg/mL。
- 未观察到性别影响,未报告严重不良事件。
关键数值与推荐
- 给药方案:厄他培南1 g静脉给药,血液透析后每周三次。
- 药代参数:消除半衰期19.3±6.6 h;峰浓度343±48 µg/mL;清除率2±0.5 mL/min;Vss 3295±1187 mL;AUCinf 7494±1424 h·µg/mL。
临床怎么用
- 血液透析患者使用厄他培南时需考虑半衰期延长,可参考血液透析后每周三次1 g的给药方案。
- 该方案基于药代动力学推导,用于潜在抗菌治疗时仍需结合临床评估。
局限性
- 研究样本量小,仅7例非感染住院患者。
- 为单次给药药代动力学研究,未评估延长疗程下的临床疗效与安全性。
- 为单中心、开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous pharmacokinetic studies demonstrated an increase in serum ertapenem concentrations with decreasing kidney function, including patients receiving renal replacement therapy. This study evaluated the pharmacokinetic parameters of ertapenem in patients receiving hemodialysis. METHODS: This prospective, single-center, open-label study examined the pharmacokinetics of a single intravenous (IV) dose of ertapenem 1 g in seven hospitalized noninfected patients undergoing hemodialysis. Blood samples were collected prior to ertapenem administration and at 0.5, 1, 2, 6, 12 and 48 hours (h) after administration. Ertapenem concentrations were determined by validated liquid chromatography mass spectrometry assay. RESULTS: Following an IV bolus of 1 g ertapenem, plasma concentrations declined relatively slowly with a mean ±standard deviation (SD) elimination half-life of 19.3 ±6.6 h. Plasma concentrations were similar in all subjects, with maximum mean plasma concentration observed of 343±48 µg/mL postdose. The mean ±SD values for systemic plasma clearance (CL) and volume of distribution at steady state (Vss) were 2±0.5 mL/min and 3295±1187 mL, respectively. The area under the curve for 0 h-∞ (AUCinf) was 7494 ±1424 h•µg/mL. No gender effect was observed and no serious adverse events were reported. CONCLUSIONS: Ertapenem half-life was prolonged in hemodialysis patients. Considering the nonrenal clearance and the expected 70% removal with high-efficacy hemodialysis, the dose of 1 g ertapenem, three times weekly, after hemodialysis may produce pharmacodynamically sufficient exposure for potential antimicrobial efficacy. Further studies are warranted to assess the clinical efficacy and safety of this dose with prolonged duration of therapy.
引用
- Hsaiky LM, Salinitri FD, Wong J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Nephrol Dial Transplant. 2019. PMID: 29992286. doi:10.1093/ndt/gfy166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。